Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Topical GSK1278863 in Healthy Volunteers and Diabetic Patients, and Repeat Doses of GSK1278863 in Diabetic Patients for the Treatment of Diabetic Foot Ulcer
Phase of Trial: Phase I
Latest Information Update: 23 May 2017
At a glance
- Drugs Daprodustat (Primary)
- Indications Diabetic foot ulcer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 16 May 2017 Status changed from recruiting to completed.
- 08 Nov 2016 Planned End Date changed from 1 Aug 2016 to 1 Jun 2017.
- 08 Nov 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Jun 2017.